Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

FDA Approves Phathom’s Voquezna Triple and Dual PAK

May 3, 2022, 9:50 PM

Phathom Pharmaceuticals says FDA approved Voquezna Triple Pak and Dual Pak for treatment of Heliobacter pylori infection in adults.

  • Shares rose 8.7% in post-market trading
  • Phathom in-licensed the U.S., European, and Canadian rights to vonoprazan, an ingredient in Voquezna, from Takeda

NOTE

  • Phathom Pharmaceuticals Inc. rose 12.4% in postmarket trading to $16.45 as of 5:46 p.m. New York time
    • The average 12-month price target of $52.67 is 220.2% above the current price
    • 6 buys, 1 holds, 0 sells

To view the source of this information, click here

To contact the reporter on this story:
Jim Silver in New York at ...